rs63751122 — APP L723P (Australian)

Rare pathogenic missense variant in APP near the gamma-secretase cleavage site causing autosomal dominant early-onset familial Alzheimer's disease; the "Australian" mutation first identified in an early-onset kindred, increasing amyloid-beta42/43 production 1.4- to 1.9-fold

See your personal result for APP

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

APP L723P — The Australian Mutation at the Gamma-Secretase Cleavage Site

The amyloid precursor protein (APP) is expressed throughout the brain, where it is processed by a cascade of secretase enzymes. When cleavage goes wrong — as it does in familial Alzheimer's disease — the result is excess production of amyloid-beta 42/4311 amyloid-beta 42/43
The longer, more aggregation-prone forms of Aβ; elevated Aβ42 relative to Aβ40 is the earliest detectable pathological event in Alzheimer's disease, which forms the dense plaques that drive neurodegeneration.

The L723P variant (rs63751122) — known informally as the "Australian mutation" after the family in which it was first identified — substitutes a leucine at position 723 with proline. This position lies immediately adjacent to the gamma-secretase ε-cleavage site22 immediately adjacent to the gamma-secretase ε-cleavage site
the position where presenilin-containing gamma-secretase first cuts the APP transmembrane domain, initiating the stepwise trimming that ultimately determines whether Aβ40 or the longer, more toxic Aβ42/43 peptides are produced within the APP transmembrane domain. The substitution profoundly disturbs this cleavage geometry and consistently drives overproduction of the more pathogenic amyloid fragments.

The G allele is extraordinarily rare in population databases: only one copy has been identified in over 800,000 alleles sequenced by gnomAD, observed in a single individual of European ancestry. This rarity is exactly what would be expected for a fully penetrant autosomal dominant disease mutation that causes early death before reproductive age or significantly reduces fitness.

The Mechanism

Proline is unique among amino acids in its cyclic side chain, which rigidly constrains the backbone dihedral angles and functions as a helix-breaker. Introducing proline at position 723 within the APP transmembrane helix creates a sharp kink in an otherwise straight α-helical structure. Bocharov et al. 201933 Bocharov et al. 2019
Using NMR spectroscopy in membrane-mimicking bicelles combined with molecular dynamics simulations — the most direct structural characterization of any APP transmembrane disease mutation showed that L723P causes "local unfolding of the C-terminal turn of the APP TM domain helix" and dramatically increases water accessibility at the ε-cleavage site where gamma-secretase first engages the substrate.

This structural disruption shifts the balance between the two gamma-secretase cleavage cascades: the ε49 pathway (producing predominantly Aβ40) is suppressed, while the ε48 pathway (producing predominantly Aβ42/43) is favored. The AlzForum mutation database records that L723P causes "increased Aβ48 levels, reduced Aβ48 trimming, and nearly abrogated Aβ49 production" — a cleavage signature consistent with overwhelming overproduction of the more aggregation-prone amyloid species.

The original discovery paper — Kwok et al. 200044 Kwok et al. 2000 — confirmed the functional consequence directly: expression of L723P mutant APP in CHO cells produced a 1.4- to 1.9-fold increase in Aβ42/43 production relative to wild-type, and the mutant protein was also capable of inducing apoptosis. More recent work by Krasnobaev et al. 202355 Krasnobaev et al. 2023 added a biophysical dimension: in lipid bilayers without cholesterol, L723P APP fragments form anomalous annular structures and membrane clusters, suggesting the mutation may also disrupt normal APP trafficking and membrane compartmentalization in a cholesterol-dependent manner — potentially relevant to age-related changes in neuronal membrane lipid composition.

The Evidence

The clinical evidence for pathogenicity is well-established. The original Australian kindred66 original Australian kindred
Kwok et al., Ann Neurol 2000 presented with early-onset Alzheimer's disease consistent with autosomal dominant transmission. Subsequent detection of L723P in a Serbian early-onset AD patient by Dobricic et al. 201277 Dobricic et al. 2012 — where it co-occurred with a PSEN1 variant in the same individual — confirmed its appearance beyond the founding family. The AlzForum mutations database classifies the variant as pathogenic for Alzheimer's disease.

The broader DIAN (Dominantly Inherited Alzheimer Network) longitudinal programme has enrolled carriers of autosomal dominant Alzheimer mutations including APP and PSEN1/2 variants, generating the most detailed picture of the presymptomatic trajectory available. Daniels et al. 202688 Daniels et al. 2026, reporting 15 years of longitudinal DIAN data, documented that amyloid pathology begins accumulating approximately 35 years before expected symptom onset, with phosphorylated tau rising ~20–25 years before symptoms and neurodegeneration markers ~15 years before. This timeline implies that a carrier with an expected onset in their early 50s already has measurable amyloid accumulation in their late teens or early twenties — long before any clinical signs appear.

Practical Actions

Discovery of a fully penetrant autosomal dominant AD mutation shifts clinical management entirely toward surveillance, genetic counseling, and trial participation. The key interventions are:

Specialist referral: Carriers should be referred to an Alzheimer's disease specialist familiar with familial early-onset cases. The DIAN network (dian.wustl.edu) and similar programmes offer access to observational studies and prevention trials that are only available to ADAD mutation carriers.

CSF and imaging biomarkers: Quantitative amyloid PET or CSF Aβ42/Aβ40 ratio provides the earliest actionable signal — a rising amyloid burden changes clinical management toward earlier specialist monitoring and trial eligibility. Plasma p-tau 217 is emerging as a less invasive option.

Vascular risk minimization: Among ADAD mutations, there is emerging evidence that cardiovascular risk factors (hypertension, dyslipidemia, diabetes) accelerate the clinical timeline. Minimizing these through condition-specific management is justified even in the absence of symptoms.

Family genetic counseling: L723P follows autosomal dominant inheritance — each first-degree relative (parent, sibling, child) has a 50% chance of carrying the same variant. Referral to a genetic counselor facilitates presymptomatic testing decisions for relatives who want that information, and supports those who do not.

Interactions

L723P acts at the same gamma-secretase cleavage site as other APP transmembrane domain mutations (rs63750066 / A713T, rs63750432 / V717I, rs63750671 / V717F), and as PSEN1 and PSEN2 mutations (the presenilin proteins are the catalytic subunit of gamma-secretase). Any co-occurrence of L723P with another pathogenic PSEN1 or PSEN2 variant would represent two independent insults to the same enzymatic step — an extreme but documented scenario (Dobricic et al. 2012 identified exactly this configuration: one patient with both APP L723P and PSEN1 R108Q). APOE ε4 genotype (rs7412, rs429358) is associated with earlier onset and greater amyloid burden in ADAD carriers and should be reported alongside L723P results in clinical settings.

Genotype Interpretations

What each possible genotype means for this variant.

AA Non-carrier Normal

No APP L723P mutation — standard amyloid precursor processing

You do not carry the L723P (Australian) mutation in the APP gene. Your amyloid precursor protein has the standard leucine at position 723, preserving the normal transmembrane helical structure at the gamma-secretase cleavage site. The G allele that causes this familial Alzheimer's disease variant is found in fewer than 1 in 400,000 individuals in population databases. Your APP-L723 risk for this specific familial Alzheimer's variant is at general population background level.

AG Carrier (Heterozygous) High Risk

Carrier of one APP L723P allele — autosomal dominant familial Alzheimer's disease mutation

The L723P variant introduces a helix-breaking proline at the C-terminal end of the APP transmembrane domain, immediately adjacent to where gamma-secretase performs its first cut (the ε-cleavage). NMR structural studies demonstrate that this disrupts the local helical structure, increases water penetration at the cleavage site, and shifts the enzymatic reaction strongly toward the Aβ48 processing cascade — producing excess Aβ42/43 at the expense of the shorter, less toxic Aβ40. This is the molecular event that drives early amyloid accumulation.

Data from the DIAN longitudinal programme — which tracks carriers of APP and PSEN1/2 mutations before and after symptom onset — document that amyloid accumulation in ADAD mutation carriers is detectable by PET imaging roughly 35 years before expected symptom onset. Plasma phosphorylated-tau 217 rises approximately 20–25 years before expected onset. This means a carrier who would otherwise develop symptoms in their early 50s likely has measurable amyloid pathology by their late teens or early twenties.

Variant rarity (only one G allele observed in >800,000 gnomAD exome alleles) is consistent with strong negative selection pressure from a fully penetrant early-onset lethal condition — not with benign variation.

Each first-degree relative (parent, sibling, and child) has a 50% probability of carrying this variant. The decision whether to seek presymptomatic testing is deeply personal; genetic counseling provides the right framework for those conversations.

GG Homozygous (Theoretical) High Risk

Two copies of APP L723P — both APP alleles pathogenic; this genotype has never been observed in population databases

Theoretical homozygosity for a fully penetrant autosomal dominant AD mutation is an extreme scenario. For comparison, homozygous carriers of the APP A713T Calabrian mutation were studied by Conidi et al. 2015 in a six-generation Italian family, and they were not observably more severely affected or earlier-onset than heterozygotes — suggesting the dominant disease mechanism is already at maximum effect with a single pathogenic allele.

If this result is confirmed, it should be interpreted with full awareness that laboratory or data errors (sample mix-up, variant calling artefact) are a realistic alternative explanation for homozygosity of this variant, given its extreme rarity. Orthogonal confirmation by Sanger sequencing or a second independent platform is mandatory before clinical management is planned.